- Starpharma’s (ASX:SPL) Chief Executive Officer, Dr Jackie Fairely, resigns after 16 years in the role
- During her tenure, Dr Fairley “transformed” Starpharma from a startup to a “mature organisation” with multiple commercial partnerships
- Dr Jackie will remain available under a consultancy agreement for 12 months after her successor commences to provide Starpharma “maximum flexibility” for the transition
- Starpharma is up 1.35 per cent, trading at 37.5 cents at 11:35 am AEST
Starpharma’s (SPL) CEO, Dr Jackie Fairley, has announced her retirement after 16 years at the company’s helm.
Dr Fairley intends to retire during 2024, following an orderly transition.
“Under her leadership and vision, Starpharma has successfully transformed from a startup with promising technology to a mature organisation with multiple commercial partnerships, marketed products around the world, and a strong portfolio of preclinical and clinical-stage assets,” Starpharma Chair Rob Thomas said.
“She has also built a stable and highly skilled workforce and positive organisational culture which will serve the company well into the future.”
Dr Jackie Fairley said she was “extremely proud” of what was achieved during her time at Starpharma.
“It has been a privilege to work with the incredibly talented and dedicated Starpharma team, and I strongly believe the company has an exciting future ahead.”
The outgoing CEO and board have agreed she will remain available under a consultancy agreement for up to 12 months after her successor commences.
The board has contracted executive search firm Heidrich & Struggles to conduct a global search for a new CEO.
Starpharma was up 1.35 per cent, trading at 37.5 cents at 11:35 am AEST.